Cubist Systematic Strategies LLC decreased its position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 47.4% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 101,653 shares of the biopharmaceutical company's stock after selling 91,691 shares during the quarter. Cubist Systematic Strategies LLC owned approximately 0.16% of Xencor worth $1,924,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently made changes to their positions in the company. Norges Bank bought a new position in Xencor in the 4th quarter worth about $6,909,000. Vanguard Group Inc. boosted its stake in Xencor by 1.7% in the 4th quarter. Vanguard Group Inc. now owns 6,767,249 shares of the biopharmaceutical company's stock worth $143,669,000 after purchasing an additional 115,886 shares during the period. Jacobs Levy Equity Management Inc. bought a new position in Xencor in the 1st quarter worth about $4,608,000. Entropy Technologies LP bought a new position in Xencor in the 1st quarter worth about $573,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in Xencor by 9.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,819,656 shares of the biopharmaceutical company's stock worth $84,530,000 after purchasing an additional 335,881 shares during the period.
Xencor Price Performance
Shares of NASDAQ XNCR traded down $0.47 during trading hours on Tuesday, reaching $19.64. 1,291,302 shares of the stock traded hands, compared to its average volume of 633,631. The company has a market capitalization of $1.21 billion, a P/E ratio of -8.97 and a beta of 0.66. The company has a quick ratio of 6.92, a current ratio of 6.92 and a debt-to-equity ratio of 0.02. Xencor, Inc. has a 52-week low of $15.31 and a 52-week high of $26.84. The company's 50-day simple moving average is $18.64 and its two-hundred day simple moving average is $20.28.
Xencor (NASDAQ:XNCR - Get Free Report) last announced its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.25). Xencor had a negative net margin of 132.74% and a negative return on equity of 28.23%. The company had revenue of $16.96 million during the quarter, compared to the consensus estimate of $21.13 million. During the same quarter in the previous year, the firm posted ($0.37) EPS. The business's revenue for the quarter was down 62.7% compared to the same quarter last year. Equities research analysts forecast that Xencor, Inc. will post -4.15 EPS for the current year.
Insider Buying and Selling at Xencor
In other Xencor news, VP John R. Desjarlais sold 36,329 shares of the business's stock in a transaction that occurred on Tuesday, July 9th. The stock was sold at an average price of $18.32, for a total value of $665,547.28. Following the completion of the sale, the vice president now owns 192,319 shares in the company, valued at $3,523,284.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 5.23% of the company's stock.
Analyst Upgrades and Downgrades
XNCR has been the subject of several analyst reports. BMO Capital Markets restated an "outperform" rating and issued a $32.00 target price on shares of Xencor in a research note on Tuesday, August 6th. JPMorgan Chase & Co. lowered their price target on Xencor from $30.00 to $27.00 and set an "overweight" rating on the stock in a report on Wednesday, July 31st. Raymond James lowered their price target on Xencor from $58.00 to $40.00 and set a "strong-buy" rating on the stock in a report on Friday, June 14th. Wedbush reaffirmed an "outperform" rating and issued a $34.00 price target on shares of Xencor in a report on Monday, September 9th. Finally, Royal Bank of Canada raised their price target on Xencor from $31.00 to $34.00 and gave the company an "outperform" rating in a report on Thursday, September 26th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Xencor currently has a consensus rating of "Moderate Buy" and a consensus price target of $34.78.
Check Out Our Latest Analysis on XNCR
About Xencor
(
Free Report)
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
See Also
Before you consider Xencor, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xencor wasn't on the list.
While Xencor currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
